SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous hepatitis B virus (HBV)-specific T ...

The UK’s proposed regulations would provide the legal framework for POC manufacturing, including quality assurance.

The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License Application (BLA) for prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis ...

The Global Institute of Stem Cell Therapy and Research (GIOSTAR), based here which is focused on developing innovative ...

Achievement of first significant research milestone triggers an option exercise payment of $10 million from AstraZenecaAstraZeneca will progress ...

Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit ...

If approved, pz-cel would be the first autologous, cell-based gene therapy for RDEB, and the first RDEB treatment designed to provide collagen VII expression at wound sites via a stably integrated ...

Alloy Therapeutics inks collaboration & license agreement with Takeda to develop cell therapy platform: Tokyo Friday, November 22, 2024, 17:00 Hrs [IST] Alloy Therapeutics Inc. (A ...

a first-in-class autologous hepatitis B virus (HBV)-specific T-cell receptor-engineered T Cell (TCR-T) therapy targeting hepatitis B surface antigen (HBsAg). The data was presented at the 2024 AASLD ...

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell ...

Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.

Immune-cell therapy shrank children's brain tumors, restored neurologic function and—for one participant—erased all ...